By Jiazhong (Jason) Luo, Ph.D. and Frederick R. Ball
Recently, the Supreme Court of the United States unanimously reversed the Federal Circuit in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., holding that Amarin failed to state a claim
Duane Morris Life Sciences Law
Duane Morris Life Sciences Law, published by Duane Morris LLP, focuses on legal issues affecting the life sciences sector. The blog covers topics such as patent eligibility and intellectual property protection for emerging technologies like AI and diagnostics, regulatory compliance in financing and exit strategies, product liability concerns, and health economics related to personalized medicine. It also addresses legal challenges in wearable technology and provides insights on navigating complex intersections of scientific innovation, investment, and legal frameworks within the life sciences industry.
Blog Authors
Latest from Duane Morris Life Sciences Law
Federal Regulatory Response to New World Screwworm and Implications for the Agricultural and Animal Health Industries
By Driscoll R. Ugarte, Brandon A. Chan, Ph.D., Victoria (Tori) Hawekotte and Taylor Hertzler
The New World screwworm is a parasitic fly whose larvae burrow into the flesh of warm-blooded animals, feeding on healthy tissue and causing myiasis…
FDA Announces FY2026 Grant Funding for Animal and Veterinary Innovation Centers
By Duane Morris
By Driscoll R. Ugarte and Taylor Hertzler
On May 4, 2026, the U.S. Food and Drug Administration’s Center for Veterinary Medicine opened a new round of grant funding for its Animal and Veterinary Innovation Centers program via a notice of…
DOJ Proposes Antitrust Settlement with Data Consultant, Requiring Sweeping Changes to Meat Industry Data-Sharing Practices
By Duane Morris
By Driscoll R. Ugarte, Sean P. McConnell and Taylor Hertzler
On May 7, 2026, the U.S. Department of Justice’s Antitrust Division filed a proposed settlement in the U.S. District Court for the District of Minnesota to resolve claims…
Montana’s Draft Rules for Experimental Treatment Centers Under SB 535 – Key Highlights for Stakeholders
By Duane Morris
By Vicki G. Norton, Ph.D. and Brandon A. Chan, Ph.D.
Montana Senate Bill 535 established a framework for licensed experimental treatment centers to offer patients access to experimental treatments that have completed Phase I clinical trials but have not…
Ambiguity of Measurement Conditions for Relevant Chemical Property Leads to Federal Circuit Affirming Noninfringement of Epoprostenol Patents
By Duane Morris
By Thomas J. Kowalski, Ryan C. Smith, Ph.D. and Brandon A. Chan, Ph.D.
Numerical patent claim limitations can be helpful to both define the metes and bounds of the claimed subject matter to deter potential infringers as well as…
Highlights from the Food & Drug Law Institute’s Annual Conference 2026
By Duane Morris
By Frederick R. Ball and Victoria (Tori) Hawekotte
Attorneys from Duane Morris’ Life Sciences and Medical Technologies Industry Group attended the Food & Drug Law Institute’s Annual Conference, which featured participation from senior leadership at the Food and Drug Administration.…
DEA Issues Order Expediting Cannabis Rescheduling to Schedule III
By Duane Morris
By Paul P. Josephson, Michael D. Schwamm and Tracy Gallegos
On April 22, 2026, a final order issued by the Acting Attorney General and the Drug Enforcement Administration took effect, fundamentally altering the federal regulatory landscape for marijuana. The…
The Healthcare Class Action Review – 2026: A Deep Dive Into Healthcare Litigation Trends
By Duane Morris
By Gerald L. Maatman, Jr. and Jennifer A. Riley
The Healthcare Class Action Review – 2026 is a comprehensive new eBook that examines the most significant developments in healthcare-related class actions over the past year. Healthcare organizations today operate at the…
DOJ: First DEI-Related FCA Case Is Settled
By Duane Morris
On April 10, 2026, the U.S. Department of Justice announced its first False Claims Act settlement arising from allegations that an organization’s diversity, equity and inclusion programs constituted illegal discrimination. The $17 million settlement, announced by DOJ’s…